Retatrutide

Retatrutide is an experimental triple-hormone-receptor agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors to promote weight loss and improve glycemic control.

It is currently in Phase 3 clinical trials and is not yet FDA-approved for commercial use.

Mechanism and Efficacy Retatrutide functions by simultaneously activating three metabolic pathways: GLP-1(suppresses appetite and slows digestion), GIP (enhances insulin secretion and reduces food intake), and glucagon(increases energy expenditure and fat breakdown).

Clinical trials have demonstrated significant results, with participants losing up to 24.2% of their body weight(approx. 57.8 lbs) over 48 weeks in Phase 2 studies. It also showed substantial improvements in HbA1c levels for patients with Type 2 diabetes.